Association of Serum Hepatocyte Growth Factor with Pericardial Fat Volume in Patients with Coronary Artery Disease

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Jul 30

PMID 26221348

Authors

Jingning Liu

Zhengxia Liu

Shikun Cai

Peng Lu

Xiang Lu

Gang Peng

Affiliations

Soon will be listed here.

Abstract

Hepatocyte growth factor (HGF), as a metabolic regulator, was shown to be secreted by adipose tissue and associated with metabolic syndrome (MS) and coronary artery disease (CAD). Pericardial fat, as a visceral fat, was found to be a significant predictor of CAD. We investigated the relationship between serum HGF levels and pericardial fat volume (PFV) in individuals aged between 40-65 years without liver or renal diseases, and also without medicine consumption. Serum HGF levels were found to be significantly higher in participants with CAD than those without CAD (P<0.001). In addition, the serum HGF levels had a significant positive correlation with the PFV in all the participants (r=0.485, P<0.001). Multivariate linear regression demonstrated that the serum HGF levels were significantly associated with PFV (β value=0.454, P<0.001) after adjustment for the metabolic parameters. Further regression assessment found that the serum HGF levels were significantly associated with PFV in participants with CAD (β value=0.586, P<0.001). The serum HGF levels were significant and independent predictors for determining the presence of CAD (OR=1.002, 95% CI: 1.000-1.004, P=0.011). This study therefore demonstrated that the serum HGF levels positively correlated with PFV in participants with CAD and can therefore be a significant predictor for the presence of CAD.

References

Tashiro K, Hagiya M, Nishizawa T, Seki T, Shimonishi M, Shimizu S . Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc Natl Acad Sci U S A. 1990; 87(8):3200-4. PMC: 53863. DOI: 10.1073/pnas.87.8.3200. View

Nishimura M, Ushiyama M, Nanbu A, Ohtsuka K, Takahashi H, Yoshimura M . Serum hepatocyte growth factor as a possible indicator of arteriosclerosis. J Hypertens. 1997; 15(10):1137-42. DOI: 10.1097/00004872-199715100-00011. View

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

Gaborit B, Kober F, Jacquier A, Moro P, Cuisset T, Boullu S . Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes (Lond). 2011; 36(3):422-30. DOI: 10.1038/ijo.2011.117. View

Zarnegar R, Michalopoulos G . The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995; 129(5):1177-80. PMC: 2120475. DOI: 10.1083/jcb.129.5.1177. View

Malavazos A, Ermetici F, Coman C, Corsi M, Morricone L, Ambrosi B . Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol. 2006; 121(1):132-4. DOI: 10.1016/j.ijcard.2006.08.061. View

Morishita R, Moriguchi A, Higaki J, Ogihara T . Hepatocyte growth factor (HGF) as a potential index of severity of hypertension. Hypertens Res. 1999; 22(3):161-7. DOI: 10.1291/hypres.22.161. View

Vela D, Buja L, Madjid M, Burke A, Naghavi M, Willerson J . The role of periadventitial fat in atherosclerosis. Arch Pathol Lab Med. 2007; 131(3):481-7. DOI: 10.5858/2007-131-481-TROPFI. View

Suzuki H, Murakami M, Kondo T, Shibata M, Ezumi H, Okabayashi H . [Changes of serum hepatocyte growth factor in coronary artery disease]. J Cardiol. 2000; 35(5):319-24. View

10.

Lenihan D, Osman A, Sriram V, Aitsebaomo J, Patterson C . Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease. Am J Physiol Heart Circ Physiol. 2003; 284(5):H1507-12. DOI: 10.1152/ajpheart.00429.2002. View

11.

Rosito G, Massaro J, Hoffmann U, Ruberg F, Mahabadi A, Vasan R . Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008; 117(5):605-13. DOI: 10.1161/CIRCULATIONAHA.107.743062. View

12.

Iacobellis G, Leonetti F, Singh N, Sharma A . Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol. 2006; 115(2):272-3. DOI: 10.1016/j.ijcard.2006.04.016. View

13.

Nishimura M, Ushiyama M, Nanbu A, Ohtsuka K, Yoshimura M . [Vascular endothelium-related factors and atherosclerosis/arteriosclerosis: serum hepatocyte growth factor as a possible indicator of vascular lesions]. Rinsho Byori. 1998; 46(7):671-7. View

14.

Rubin J, Bottaro D, Aaronson S . Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta. 1993; 1155(3):357-71. DOI: 10.1016/0304-419x(93)90015-5. View

15.

Nafakhi H, Al-Mosawi A, Al-Nafakh H, Tawfeeq N . Association of pericardial fat volume with coronary atherosclerotic disease assessed by CT angiography. Br J Radiol. 2014; 87(1038):20130713. PMC: 4075553. DOI: 10.1259/bjr.20130713. View

16.

Kamimoto M, Mizuno S, Matsumoto K, Nakamura T . Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem Biophys Res Commun. 2009; 380(2):333-7. DOI: 10.1016/j.bbrc.2009.01.080. View

17.

Konya H, Miuchi M, Satani K, Matsutani S, Tsunoda T, Yano Y . Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus. World J Diabetes. 2014; 5(5):678-88. PMC: 4138591. DOI: 10.4239/wjd.v5.i5.678. View

18.

Konishi M, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Matsubara J . Association of pericardial fat accumulation rather than abdominal obesity with coronary atherosclerotic plaque formation in patients with suspected coronary artery disease. Atherosclerosis. 2009; 209(2):573-8. DOI: 10.1016/j.atherosclerosis.2009.10.008. View

19.

Mizuno S, Nakamura T . Prevention of neutrophil extravasation by hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction in mouse ischemic kidneys. Am J Pathol. 2005; 166(6):1895-905. PMC: 1602426. DOI: 10.1016/S0002-9440(10)62498-4. View

20.

Iacobellis G, Barbaro G . The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res. 2008; 40(7):442-5. DOI: 10.1055/s-2008-1062724. View